Brookline Capital Management Predicts HURA Q2 Earnings

TuHURA Biosciences, Inc. (NASDAQ:HURA - Free Report) - Brookline Capital Management issued their Q2 2025 earnings per share estimates for TuHURA Biosciences in a report issued on Monday, June 23rd. Brookline Capital Management analyst K. Raja expects that the company will post earnings of ($0.15) per share for the quarter. Brookline Capital Management currently has a "Strong-Buy" rating on the stock. Brookline Capital Management also issued estimates for TuHURA Biosciences' Q3 2025 earnings at ($0.15) EPS, Q4 2025 earnings at ($0.15) EPS, FY2025 earnings at ($0.60) EPS, FY2026 earnings at ($0.58) EPS, FY2027 earnings at ($0.57) EPS, FY2028 earnings at ($0.43) EPS and FY2029 earnings at $0.08 EPS.

HURA has been the topic of several other reports. Wall Street Zen lowered shares of TuHURA Biosciences from a "hold" rating to a "sell" rating in a research note on Saturday, June 14th. HC Wainwright restated a "buy" rating and issued a $12.00 price objective on shares of TuHURA Biosciences in a report on Friday, May 16th. One research analyst has rated the stock with a sell rating, three have given a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Buy" and an average price target of $12.67.

TuHURA Biosciences Price Performance

Shares of HURA stock opened at $2.35 on Wednesday. TuHURA Biosciences has a 12 month low of $1.80 and a 12 month high of $7.93. The company's fifty day simple moving average is $3.39 and its 200-day simple moving average is $3.72.

TuHURA Biosciences (NASDAQ:HURA - Get Free Report) last released its earnings results on Thursday, May 15th. The company reported ($0.15) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.02).

Hedge Funds Weigh In On TuHURA Biosciences

Institutional investors have recently added to or reduced their stakes in the company. Accent Capital Management LLC bought a new position in shares of TuHURA Biosciences in the 4th quarter valued at about $29,000. TT Capital Management LLC acquired a new stake in TuHURA Biosciences in the 4th quarter valued at about $41,000. Jefferies Financial Group Inc. bought a new position in TuHURA Biosciences during the fourth quarter worth about $54,000. Bank of America Corp DE acquired a new position in TuHURA Biosciences during the fourth quarter worth approximately $59,000. Finally, Charles Schwab Investment Management Inc. acquired a new position in TuHURA Biosciences during the fourth quarter worth approximately $61,000. 0.62% of the stock is currently owned by institutional investors and hedge funds.

About TuHURA Biosciences

TuHURA Biosciences, Inc NASDAQ: HURA is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA's lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.